维普中文期刊产品整合服务

A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant

查看全文 作　　者：Zezhong [1]Liu;Jasper Fuk-Woo [2,3,4]Chan;Jie [1]Zhou;Meiyu [5,6]Wang;Qian [1]Wang;Guangxu [1]Zhang;Wei [1]Xu;Kenn Ka-Heng [4]Chik;Yilong [7]Zhang;Youchun [5,6]Wang;Kwok-Yung [2,3,4]Yuen;Lu [1]Lu;Shibo [1]Jiang 高影响力作者 机构地区：[1]Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),School of Basic Medical Sciences,Shanghai Frontiers Science Center of Pathogenic Microbes and Infection,Shanghai Institute of Infectious Disease and Biosecurity,Fudan University,Shanghai,China;[2]State Key Laboratory of Emerging Infectious Diseases,Carol Yu Centre for Infection,Department of Microbiology,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China.;[3]Department of Clinical Microbiology and Infection Control,The University of Hong Kong-Shenzhen Hospital,Shenzhen,Guangdong,China.;[4]Centre for Virology,Vaccinology and Therapeutics,Hong Kong Science and Technology Park,Hong Kong,China.;[5]Graduate School of Peking Union Medical College,Beijing,China.;[6]Division of HIV/AIDS and Sex-transmitted Virus Vaccines,Institute for Biological Product Control,National Institutes for Food and Drug Control(NIFDC),Beijing,China.;[7]Fulgent Pharma LLC.,4978 Santa Anita Avenue,Temple City,CA,USA.高影响力机构 出　　处：《Cell Research》索引2022年第32卷第5期,共3页高影响力期刊 基　　金：the National Natural Science Foundation of China(92169112 to S.J.;82041036 to L.L.);the Health and Medical Research Fund(COVID1903010-Project 7 to J.F.-W.C.);The Government of the Hong Kong Special Administrative Region;Health@InnoHK,Innovation and Technology Commission,The Government of the Hong Kong Special Administrative Region(to K.-Y.Y.);the National Key Research and Development Programme on Public Security Risk Prevention and Control Emergency Project(to K.-Y.Y.);the National Program on Key Research Project of China(2020YFA0707500 and 2020YFA0707504 to J.F.-W.C;2021YFC2300703 to L.L.);the National Key R&D Program of China(2021YFC2300703 to L.L.);Program of Shanghai Academic/Technology Research Leader(20XD1420300 to L.L.).and China Postdoctoral Science Foundation(2021M700840 to Z.L.). 摘　　要：Dear Editor,Since the outbreak of Coronavirus Disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection,numerous SARS-CoV-2 variants of concern(VOCs),such as Alpha(B.1.1.7),Beta(B.1.351),Gamma(P.1),and Delta(B.1.617.2),have emerged.Recently,the newly identified SARS-CoV-2 VOC,Omicron(B.1.1.529),has rapidly spread in many countries1 and is expected to replace Delta as the dominant variant circulating in the world.Compared to other VOCs,Omicron contains at least 32 mutations in spike(S)protein,including 15 mutations in the receptor-binding domain(RBD),and these mutations are known to confer resistance to neutralizing antibodies(nAbs)and sera of convalescent patients and people who have received COVID-19 vaccines.2–5 Therefore,vaccines able to induce potent and durable neutralizing antibodies against Omicron and other VOCs are urgently needed. 关 键 词：NEUTRAL acute RESPIRATORY
相关文献

参考文献(8)

引证文献(7)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费